Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

L-873724

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BackgroundSelective and reversible inhibitors of human Cathepsin K (CatK), including odanacatib (ODN), have been developed as… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
Abstract Cathepsin K (Cat K) degrades bone type I collagen and is a target for the pharmacological treatment of osteoporosis… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Cathepsin K is a lysosomal cysteine protease that is a pharmacological target for the treatment of osteoporosis. Previous studies… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Based on our previous study with trifluoroethylamine as a P2-P3 amide isostere of cathepsin K inhibitor, further optimization led… Expand
Is this relevant?
Review
2006
Review
2006
Many drug candidates contain a basic functional group that results in lysosomotropism—the accumulation of drug in the acidic… Expand
Is this relevant?